Evaluation of varicella zoster virus specific immune response after varicella vaccine immunization in elderly patients with diabetes mellitus.
Phase 2
- Conditions
- diabetes mellitus
- Registration Number
- JPRN-UMIN000004771
- Lead Sponsor
- Kitano hospital, The Tazuke Kofukai Medical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
excluding criteria: patients with acute conditions; patients with underlying diseases, malignant disease, autoimmune diseases, and renal failure with serum creatinine greater than 2; smoker; treated with steroid, immunosuppressant drugs or antiplatelet drugs; with allergic reaction against varicella vaccine or pneumococcal vaccine; dermatological disorder unable to judge if skin test reaction or not; herpes zoster patients and patients within 5 years of primary 23-valent pneumococcal polysaccharides vaccine(PPSV23).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cell-mediated immunity(skin test reaction)
- Secondary Outcome Measures
Name Time Method 1. cell-mediated immunity; interferon-gamma (IFN-g) enzyme-linked immunospot (ELISPOT) 2.immunogenicity; immune adherence hemagglutination (IAHA) 3.Safety